PLUVICTO Can Be Administered Multiple Ways and Is Administered Once Every 6 Weeks for 6 Doses^1,2,*

Dosing^1,2

• PLUVICTO solution for injection contains 7.4 GBq (200 mCi ± 10%) (at time of use)

• Slow IV injection (1 to 10 minutes) or infusion

• Pre-filled syringe

The median number of doses of PLUVICTO in the PSMAfore trial (pre-chemotherapy) was 6¹

• 63% of patients received 6 doses³

GBq, gigabecquerel; IV, intravenous; mCi, millicurie.
*Or until disease progression, or unacceptable toxicity.¹

Dose Modifications

DOSE MODIFICATIONS FOR ADVERSE REACTIONS¹

Management of adverse reactions may require temporary dose interruption, dose reduction, or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an adverse reaction persists for >4 weeks, consider permanent discontinuation of PLUVICTO. 

Recommended dosage modifications of PLUVICTO for adverse reactions¹ 

Administration

SETUP AND ADMINISTRATION OF PLUVICTO¹

General information

• PLUVICTO is administered intravenously

• Nuclear medicine health care professionals may use methods deemed appropriate and safe

• Prior to administration with PLUVICTO, a saline flush with ≥10 mL of 0.9% sterile sodium chloride must be administered to ensure patency of the IV line and minimize the risk of extravasation

• Manage cases of extravasation as per your institutional guidelines

• PLUVICTO will be administered slowly by intravenous route and followed by a saline flush

Radiation Safety

IMPORTANT NOTE REGARDING USE OF PLUVICTO⁴

Always use the principles of ALARA (as low as reasonably achievable)

ALARA is the guiding principle of radiation safety. It means that even a small radiation dose should be avoided if there is no benefit to receiving it. It includes 3 basic protective measures:

Any unused medicinal product or waste material should be disposed of in accordance with local and federal laws.